Clinical Trials Browser

Withdrawn × pembrolizumab × Dermatologic × Clear all

NCT04129515 2026-01-02

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Phase 1/2 Withdrawn

Melanoma

NCT06190249 2025-06-05

LN-144

Phase 1 Withdrawn

Melanoma

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Phase 2 Withdrawn

Melanoma

NCT05338580 2024-04-15

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Phase 2 Withdrawn

DermatologicGenitourinaryThoracic

First-line Non-small-cell Lung Cancer

NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Phase 2 Withdrawn

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT04987996 2023-06-06

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Phase 2 Withdrawn

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT04703426 2023-05-22

Sargramostim (GM-CSF) + PD-1

Phase 2 Withdrawn

Melanoma

NCT05220748 2023-04-19

RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Phase 1 Withdrawn

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Skin Neoplasms

NCT04995094 2021-11-05

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

Phase 2 Withdrawn

Melanoma

NCT03773744 2021-04-06

Pelican

Phase 1 Withdrawn

Melanoma

NCT03617224 2020-04-22

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03111901 2019-07-12

UVA-AM-002

Phase 1/2 Withdrawn

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02812693 2018-04-05

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Phase 1/2 Withdrawn

Melanoma

NCT02719015 2017-11-24

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Phase 1/2 Withdrawn

Melanoma

NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Phase 1/2 Withdrawn

DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma